Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | FADS1 | O60427 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 7/20 | 0.37 |
| ▸ | MTTP | P55157 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795030 | 0.90 | SMO (0.41) | BACE1GAASMOF2ALDH1A1 | |
| SCHEMBL6796397 | 0.85 | SMO (0.41) | KDM4EGAASMOL3MBTL1F2 | |
| SCHEMBL6795031 | 0.85 | SMO (0.40) | KDM4EGAASMOL3MBTL1F2 | |
| SCHEMBL6796112 | 0.82 | MEN1 (0.41) | BACE1F2AURKARPS6KB1TRPV4 | |
| SCHEMBL6795007 | 0.80 | SMO (0.48) | KDM4EGAASMOL3MBTL1F2 | |
| SCHEMBL6645327 | 0.80 | ALDH1A1 (0.43) | BACE1KDM4EGAAF2ALDH1A1 | |
| SCHEMBL6648457 | 0.80 | F2 (0.40) | BACE1SMOL3MBTL1F2ALDH1A1 | |
| SCHEMBL6792911 | 0.79 | SMO (0.47) | KDM4EGAASMOL3MBTL1F2 | |
| SCHEMBL6794007 | 0.78 | L3MBTL1 (0.44) | KDM4EGAASMOL3MBTL1ALDH1A1 | |
| SCHEMBL6645210 | 0.78 | F2 (0.37) | BACE1F2AURKARPS6KB1ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | BACE1 320/4885KDM4E 3114/4885GAA 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.